



RESI REDEFINING
CONFERENCE EVERY STAGE
OF INVESTMENT
SEED TO EXIT

RESI London 2025 Conference Brochure

- December 4: In-person at 11 Cavendish Square
- December 8-9: Virtual Partnering only

Presented by





**LIFE SCIENCE
NATION**

Connecting Products, Services & Capital

The [Redefining Every Stage Investments \(RESI\)](#) conference series connects start-ups and early-stage investors and strategic channel partners. RESI is uniquely cross-border and cross-domain, connecting start-ups with global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare companies.

Over the past decade, **400+** companies have raised **\$5B+** through **35+** RESI conferences and LSN products.



The first week of December is the best time in the UK for early-stage life science fundraising.

RESI London, Genesis, and ELRIG/SLAS offer better investor access, partnering, ideal for companies raising from pre-seed to Series B or in early clinical stages.

December 2

- Free course on fundraising, including networking, offered by LSN
- Free ELRIG / SLAS drug-discovery focused networking event
- Genesis welcome reception for Genesis and RESI registrants

Combo tickets are now available for purchase.



December 3

- Genesis “Maximizing Returns from Life Science Innovation” KOL & partnering event
- Genesis evening reception

December 4

- RESI London fundraising & partnering event, featuring 200 investors & in-licensors
- RESI London evening reception

December 8 – 9

- RESI London virtual partnering



Partnering Overview Partnering is one of the most valuable facets of RESI conferences. The partnering platform is designed to match attendees based on sector, indication, phase of development, etc. (see below to see criteria), eliminating the question, “Is this a good fit for my needs?” Fundraising companies match with a diverse pool of investors who fit both development stage and product set. Investors and strategic partners can explore the latest innovation in a format that easily connects them with products they are most interested in. Sponsors, exhibitors, and providers also can review attendee profiles to find the best fit for their services.

How Does it Work? Partnering providing time to upload personal schedules and company profiles, as well as review and request meetings with attendees using the filters based on which attendees you are most interested in meeting.

LSN hosts free workshops to review platform function and provide tips for anyone who is new or inexperienced with partnering events. Click the video to view a partnering tutorial.

SEARCH FOR SPECIFIC INVESTORS

Sector interest

-- select --

- ☐ Biotechnology - Therapeutics and Diagnostics
- ☐ Biotechnology - R&D Services
- ☐ Biotechnology - Other
- ☐ Pharma (fully integrated)
- ☐ Medical Technology
- ☐ HealthTech

Medtech sector (0)

-- select --

- ☐ Hospital hardware
- ☐ Imaging
- ☐ Non-active implantable devices
- ☐ Ophthalmic and optical devices
- ☐ Regenerative Medicine
- ☐ Reusable instruments
- ☐ Single use devices
- ☐ Technical aids for disabled persons
- ☐ Wound care

Indication interest

-- select --

- ☐ Cardiovascular
- ☐ Conditions originating in the peri
- ☐ Congenital malformations, deform
- ☐ Digestive system
- ☐ Diseases of the blood and blood-i
- ☐ Diseases of the ear

Investment stage preference

-- select --

- ☐ Seed
- ☐ Venture
- ☐ Growth

Therapeutic development phase (0)

-- select --

- ☐ Discovery
- ☐ Lead optimization
- ☐ Preclinical
- ☐ Phase I
- ☐ Phase I/II
- ☐ Phase II
- ☐ Phase II/III
- ☐ Phase III
- ☐ Pre-file

The **Standard Partnering Profile** provides filterable information about each investor's sector(s), indications(s) and phase(s) of development they seek. Attendees reviewing a standard profile can judge if they are a fit for their product offerings. Standard profiles contain:

- Allocation Information
- Investor Type
- Main Sector
- Indications
- Phase of Development
- Orphan Interest
- Capital Structure Preference
- Investment Stage
- Attending Investors
- "Book Meetings" Option

A **Premier Partnering Profile** provides exclusive access to full investor mandates, imported from LSN's database with 5,000+ profiles, including personal contact information for each investor. This information is gathered by LSN's investor research team, based on annual conversations and updates provided through one-on-one updates. **Attendees can upgrade their standard profile to premier for an additional £500.**

Premier Partnering Only Content

- Access to Investor Mandates
- Direct Contact Email
- Sectors and Sub-Sectors of Interest
- Company & Management Team Requirements

6 Dimensions Capital

Allocation Information

6 Dimensions Capital is a healthcare-focused venture capital firm formed in 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. Frontline BioVentures manages 2 funds, a RMB denominated fund and a parallel USD fund. WuXi Healthcare Ventures manages its \$250 million Fund II, with WuXi PharmaTech being the anchor. The firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from \$5 - \$25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

Sectors and Subsectors of Interest

6 Dimensions Capital is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue. Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

Company and Management Team Requirements

6 Dimensions Capital will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

Investor Type

Venture Capital

Main Sector

- Biotech Therapeutics
- Biotechnology Other
- Biotechnology R&D Services
- Diagnostics
- Healthcare IT
- Medical Technology
- Supplier & Engineering

Indications

- Blood Diseases/Immune Disorders
- Cardiovascular
- Cond. Orig. in the Prenatal Period
- Congen. Deform. & Chrom. Defects
- Digestive System
- Diseases of the Ear
- Diseases of the Eye
- Diseases of the Nervous System
- Endocrine/Nutri/Metabolic Dis.
- Ext. Causes of Morbidity & Mortality
- Genitourinary System
- Infectious and Parasitic Diseases
- Mental and Behavioral Disorders
- Musculoskeletal Sys. & Cnnc. Tiss.
- Neoplasms/Cancer/Oncology
- Other
- Pain and Inflammation
- Physical Injury/Poisoning
- Pregnancy/Childbirth & Puerperium
- Respiratory
- Skin and Subcutaneous Tissue

Therapeutic Product Development Phase

- NDA
- Phase I
- Phase II
- Phase III
- Pre-Clinical

Medtech/Diagnostic Development Phase

- Clinical
- In Development
- On the Market

Orphan Interest?

No

Capital Structure Preference

- Equity

Investment Stage

- Growth
- Seed
- Venture

Year Founded

2017

Direct Contact Email

Executive Director
Contact Email

Click To Request a Meeting
<https://digital-resi-sept.meeting-mojo.com/search?id=314001>

The **Innovator's Pitch Challenge** (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session.

(Pitch package does not include poster printing.)

Participants receive:

- A 6-min live pitching slot with 7-min investor Q&A
- Media promotion on the LSN newsletter and social media

The live Q&A sessions are available to the entire conference and include a curated panel of investor judges. All attendees are encouraged to vote for the most innovative company.

The top 3 winners will be announced on the conference website and in the Next Phase Newsletter after the conference. Winners receive free registrations to future partnering events.

Learn more



Live Pitch & Investor Q&A



IPC Winner Announcement



Social Media Promotion

"I'm really happy to have participated in RESI and the IPC format. The investors were predominantly stage-and sector-appropriate for a biotech start up... The IPC format was helpful in that we were able to post a short pitch online for on-demand viewing as well as having a 'live' discussion. Several of the panelists met with me after the panel, and I've been contacted by one investor (so far) outside the meeting after they'd seen the video pitch. I'm happy to recommend this meeting and the IPC format for early-stage biotech companies-I think this was money and time well spent for us."

- Ross Breckenridge, CEO, Arjuna Therapeutics


Panels

Panels are live onsite and made available for future viewing via the live agenda. These 50-minute discussions feature panelists and a moderator made up of active investors, strategic partners, and key industry leaders, with a diverse range of topics focused on the early-stage life science ecosystem.

In order to provide maximum value, LSN goes beyond partnering with expert panels and industry workshops – each designed with the early-stage player in mind – and available to help sponsors reach their goals.

Workshops

Workshops are designed to educate leaders of fundraising companies on elements of the early-stage landscape often overlooked, which can include patents, recruitment, intellectual property, insurance, financial management, and so much more.



RESI helps companies gain unprecedented visibility into the early-stage life science community, and also leverage [Life Science Nation](#) (LSN)'s close-knit network of key decision-makers to make promising connections with future clients.

Service providers are an important asset to the LSN community, and service provider registration increases deal pipeline and access to investor portfolios, as well as introduce early-stage companies developing the hottest new technologies in drugs, devices, diagnostics and digital health to the many opportunities available through service providers.

[Contact us to learn more!](#)



[Click to View Sponsorship Brochure](#)

Past Partners



REGISTER NOW

REGISTER NOW	Standard 3-day (Dec. 4, 8-9)	Virtual 2-day (Dec. 8-9)	RESI & Genesis Combi (Dec. 2-9)
Startup	Super Early Bird: £795 Early Bird: £895 Standard: £1095	Super Early Bird: £595 Early Bird: £695 Standard: £895	Super Early Bird: £1095 Early Bird: £1195 Standard: £1395
Service Provider			
Exhibitor	Super Early Bird: £2190 Early Bird: £2390 Standard: £2790 Includes Two 3-Day Standard Tickets and an Exhibition Table		
Tech Hub & Constituents	\$200 off on current startup rates		
	Contact us to discuss further.		
Investor	Complimentary – Learn more about terms applied.		

- Super Early Bird Rates: **Until Oct 3**
- Early Bird Rates: **Oct 4 – Oct 24**
- Standard Rates: **After Oct 24**

Want to learn more? We are available to answer questions and share additional details to help you meet your partnership goals! RESI@lifesciencenation.com